Barclays Capital Reaffirms Positive Rating on CVS Caremark (CVS)
CVS Caremark opened at 44.98 on Friday. CVS Caremark has a 1-year low of $31.30 and a 1-year high of $45.88. The company has a market cap of $57.642 billion and a price-to-earnings ratio of 17.12.
CVS Caremark last released its earnings data on Wednesday, May 2nd. The company reported $0.65 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.63 by $0.02. The company’s quarterly revenue was up 19.9% on a year-over-year basis. Analysts expect that CVS Caremark will post $0.82 EPS next quarter.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of CVS Caremark in a research note to investors on Thursday, May 10th. They now have a $47.00 price target on the stock. Separately, analysts at UBS AG (NYSE: UBS) raised their price target on shares of CVS Caremark from $49.00 to $53.00 in a research note to investors on Thursday, May 3rd. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of CVS Caremark to $52.00 in a research note to investors on Thursday, May 3rd. They now have a “buy” rating on the stock.
CVS Caremark Corporation (CVS Caremark) is a pharmacy healthcare provider in the United States. It provides pharmacy services through its pharmacy benefit management (PBM) mail order and specialty pharmacy division, Caremark Pharmacy Services; approximately 7,000 CVS/pharmacy retail stores; retail-based health clinic subsidiary, MinuteClinic, and through its online pharmacy, CVS.